-+ 0.00%
-+ 0.00%
-+ 0.00%
Anixa Biosciences Taps Curia To Provide Formulation Development Services For Anixa's Investigational Breast Cancer Vaccine In Preparation For Upcoming Phase 2 Clinical Trial
Share
Listen to the news

Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization

SAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development services for Anixa's investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial. The vaccine is being developed in collaboration with Cleveland Clinic.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending